Nancy J Sullivan

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates
    Nancy J Sullivan
    Vaccine Research Center, US National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 17:1128-31. 2011
  2. ncbi Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
    Nancy J Sullivan
    Biodefense Research Section, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 7:393-400. 2009
  3. ncbi Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 3:e177. 2006
  4. ncbi A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes, Bethesda, MD 20892 3017, USA
    Clin Vaccine Immunol 13:1267-77. 2006
  5. ncbi Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms
    Devon J Shedlock
    Biodefense Research Section, Vaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, 40 Convent Drive, MSC 3005, Bethesda, MD 20814, USA
    Virology 401:228-35. 2010
  6. ncbi Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species
    Lisa E Hensley
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Pathog 6:e1000904. 2010
  7. ncbi Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA
    Nature 424:681-4. 2003
  8. ncbi Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Virol 85:4222-33. 2011
  9. ncbi Ebolavirus vaccines for humans and apes
    Hugues Fausther-Bovendo
    VRC NIAID NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Opin Virol 2:324-9. 2012
  10. ncbi Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway
    Nancy J Sullivan
    Vaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20814, USA
    J Virol 79:547-53. 2005

Collaborators

Detail Information

Publications12

  1. ncbi CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates
    Nancy J Sullivan
    Vaccine Research Center, US National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 17:1128-31. 2011
    ..Understanding the immunologic mechanism of Ebola virus protection will facilitate the development of vaccines for Ebola and related hemorrhagic fever viruses in humans...
  2. ncbi Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule
    Nancy J Sullivan
    Biodefense Research Section, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 7:393-400. 2009
    ..This research provides a basis for bridging the gap from basic research to human vaccine responses in support of the licensing of vaccines through the animal rule...
  3. ncbi Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Med 3:e177. 2006
    ..GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine...
  4. ncbi A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial
    Julie E Martin
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes, Bethesda, MD 20892 3017, USA
    Clin Vaccine Immunol 13:1267-77. 2006
    ....
  5. ncbi Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms
    Devon J Shedlock
    Biodefense Research Section, Vaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, 40 Convent Drive, MSC 3005, Bethesda, MD 20814, USA
    Virology 401:228-35. 2010
    ....
  6. ncbi Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species
    Lisa E Hensley
    Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    PLoS Pathog 6:e1000904. 2010
    ....
  7. ncbi Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
    Nancy J Sullivan
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, Maryland 20892-3005, USA
    Nature 424:681-4. 2003
    ..This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses...
  8. ncbi Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge
    Thomas W Geisbert
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    J Virol 85:4222-33. 2011
    ..Increases in efficacy are paralleled by substantial increases in T- and B-cell responses to EBOV GP. These results suggest that Ad26 and Ad35 vectors warrant further development as candidate vaccines for EBOV...
  9. ncbi Ebolavirus vaccines for humans and apes
    Hugues Fausther-Bovendo
    VRC NIAID NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Curr Opin Virol 2:324-9. 2012
    ..Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes...
  10. ncbi Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway
    Nancy J Sullivan
    Vaccine Research Center, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20814, USA
    J Virol 79:547-53. 2005
    ..By altering the trafficking of select cellular proteins, Ebola virus GP inflicts cell damage and may facilitate immune escape by the virus...
  11. ncbi Immunopathology of highly virulent pathogens: insights from Ebola virus
    Carisa A Zampieri
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    Nat Immunol 8:1159-64. 2007
    ....
  12. ncbi Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway
    Giulia Fabozzi
    Biodefense Research Section, Vaccine Research Center, National Institutes of Health, Vaccine Research Center, 40 Convent Drive, Bldg 40 2509, Bethesda, MD 20892, USA
    J Virol 85:2512-23. 2011
    ..The presence of three suppressors highlights the relevance of host RNAi-dependent antiviral immunity in EBOV infection and illustrates the importance of RNAi in shaping the evolution of RNA viruses...